Shell Asset Management Co. Decreases Position in Edwards Lifesciences Corp (NYSE:EW)

Shell Asset Management Co. lessened its holdings in Edwards Lifesciences Corp (NYSE:EW) by 10.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,284 shares of the medical research company’s stock after selling 3,616 shares during the quarter. Shell Asset Management Co.’s holdings in Edwards Lifesciences were worth $5,901,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. National Asset Management Inc. raised its position in Edwards Lifesciences by 27.5% in the 1st quarter. National Asset Management Inc. now owns 2,753 shares of the medical research company’s stock worth $520,000 after purchasing an additional 594 shares during the period. Front Row Advisors LLC raised its position in Edwards Lifesciences by 311.3% in the 1st quarter. Front Row Advisors LLC now owns 329 shares of the medical research company’s stock worth $72,000 after purchasing an additional 249 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in Edwards Lifesciences by 11.9% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 29,780 shares of the medical research company’s stock worth $5,617,000 after purchasing an additional 3,172 shares during the period. Northwestern Mutual Investment Management Company LLC raised its position in Edwards Lifesciences by 34.2% in the 1st quarter. Northwestern Mutual Investment Management Company LLC now owns 10,874 shares of the medical research company’s stock worth $2,051,000 after purchasing an additional 2,772 shares during the period. Finally, Nvwm LLC raised its position in Edwards Lifesciences by 6.8% in the 1st quarter. Nvwm LLC now owns 2,838 shares of the medical research company’s stock worth $535,000 after purchasing an additional 181 shares during the period. Institutional investors own 81.22% of the company’s stock.

In other news, VP Larry L. Wood sold 3,566 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $207.00, for a total transaction of $738,162.00. Following the completion of the transaction, the vice president now directly owns 120,995 shares of the company’s stock, valued at $25,045,965. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 750 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $216.93, for a total transaction of $162,697.50. Following the transaction, the vice president now directly owns 18,318 shares of the company’s stock, valued at $3,973,723.74. The disclosure for this sale can be found here. Insiders have sold 95,878 shares of company stock valued at $20,047,408 over the last three months. 1.48% of the stock is owned by corporate insiders.

A number of equities analysts recently commented on EW shares. Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $230.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. UBS Group boosted their price objective on shares of Edwards Lifesciences from $255.00 to $260.00 and gave the company a “neutral” rating in a research report on Friday, January 31st. Cfra boosted their price objective on shares of Edwards Lifesciences from $201.00 to $231.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Barclays restated an “underweight” rating and issued a $155.00 price objective (down previously from $165.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. They noted that the move was a valuation call. Finally, Credit Suisse Group boosted their price objective on shares of Edwards Lifesciences from $260.00 to $262.00 and gave the company an “outperform” rating in a research report on Friday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $247.52.

Shares of EW traded up $0.31 during mid-day trading on Friday, hitting $218.81. 730,865 shares of the company traded hands, compared to its average volume of 1,052,099. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.47 and a current ratio of 3.36. The stock has a 50-day moving average price of $212.94 and a two-hundred day moving average price of $222.43. Edwards Lifesciences Corp has a 1 year low of $154.52 and a 1 year high of $247.64. The stock has a market cap of $45.13 billion, a price-to-earnings ratio of 41.84, a P/E/G ratio of 2.75 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.22. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. The firm had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the previous year, the company earned $1.32 earnings per share. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Corp will post 4.95 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Trading Strategy Methods for Individual Investors

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.